THERAPY DOSSIER · th-5710840aaa5c

Phosphocreatine

Drug · No ChEMBL mechanism record; high-energy phosphate / cardioprotective agent

Evidence & regulatory context

Mechanism: No ChEMBL mechanism record; high-energy phosphate / cardioprotective agent
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL1204644 ↗
ChEMBL max phase: 3 / 4 (development scale, not regulatory approval)
Synonyms: Phosphocreatine; Creatine phosphate; Phosphagen
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT06503016 ↗PHASE3recruiting

The Effect of Phosphocreatine on Medical Emergency Team Treated Patients

Cardiac Failure · Respiratory Failure

Enrolment: 400 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 24820764 ↗2014Reported benefit

Cardioprotective effects of phosphocreatine on myocardial cell ultrastructure and calcium-sensing receptor expression in the acute period following high level spinal cord injury.

RatSpinal cord injuryContusionSprague-Dawleymalen = 54 rats, 6 per group per time point, plus 6 sham controlsAbdominal (intraperitoneal) injection200 mg/kgAt 6, 12, 24 or 48 h after injury

Model: C7 spinal cord injury by Allen's weight-drop method

Phosphocreatine reduced myocardial ultrastructural damage and lowered calcium-sensing receptor, cardiac troponin I, creatine kinase and CK-MB levels at all time points.

Extraction: extract · Subtype source: llm · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…